

Josep M Piulats

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4122359/publications.pdf>

Version: 2024-02-01

103
papers

8,595
citations

126708

33
h-index

46693

89
g-index

106
all docs

106
docs citations

106
times ranked

10353
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 144-153.	15.2	102
2	Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor. <i>Cancers</i> , 2022, 14, 782.	1.7	12
3	Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. <i>European Urology</i> , 2022, 82, 22-30.	0.9	34
4	Facts and Hopes in Immunotherapy of Endometrial Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4849-4860.	3.2	16
5	Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. <i>European Urology</i> , 2021, 79, 722-733.	0.9	17
6	FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1491-1504.	3.2	13
7	Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 80-80.	0.8	0
8	KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)â€”pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)â€”New data after an additional 1 year of follow-up.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10-10.	0.8	10
9	Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). <i>Journal of Clinical Oncology</i> , 2021, 39, 586-598.	0.8	117
10	Survival in small choroidal melanocytic lesions with risk factors managed by initial observation until detection of tumour growth. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 251-259.	1.3	1
11	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	1.3	81
12	Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2669.	1.8	22
13	Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes. <i>Journal of Personalized Medicine</i> , 2021, 11, 331.	1.1	2
14	Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).. <i>Journal of Clinical Oncology</i> , 2021, 39, e21513-e21513.	0.8	1
15	Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9531-9531.	0.8	3
16	Overall survival benefit from tebentafusp in patients with best response of progressive disease.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9509-9509.	0.8	7
17	CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5086-TPS5086.	0.8	0
18	Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair. <i>Oncogene</i> , 2021, 40, 5042-5048.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	13.9	376
20	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3291-3299.	1.1	22
21	Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629. <i>Dermatology and Therapy</i> , 2021, 11, 1777-1790.	1.4	8
22	A single-cell tumor immune atlas for precision oncology. <i>Genome Research</i> , 2021, 31, 1913-1926.	2.4	87
23	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	3.2	12
24	61 Biomarkers of favorable prognosis guides the identification of tumor reactive CD4+ and CD8+ TILs in endometrial cancer. , 2021, 9, A69-A69.		0
25	T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1253-1265.	0.3	17
26	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	0.8	450
27	Are antiangiogenics a good "partner" for immunotherapy in ovarian cancer?. <i>Angiogenesis</i> , 2020, 23, 543-557.	3.7	10
28	Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). <i>Journal of Clinical Oncology</i> , 2020, 38, 2916-2925.	0.8	170
29	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	0.8	448
30	Role of POLE and POLD1 in familial cancer. <i>Genetics in Medicine</i> , 2020, 22, 2089-2100.	1.1	76
31	PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. <i>Cancer Management and Research</i> , 2020, Volume 12, 10251-10260.	0.9	5
32	High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. <i>Cancers</i> , 2020, 12, 2950.	1.7	19
33	Sensitivity of cervicovaginal cytology in endometrial carcinoma: A systematic review and meta-analysis. <i>Cancer Cytopathology</i> , 2020, 128, 792-802.	1.4	23
34	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	1.4	32
35	Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 763-766.	0.9	9
36	Lung metastases share common immune features regardless of primary tumor origin. , 2020, 8, e000491.		63

#	ARTICLE	IF	CITATIONS
37	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	3.2	273
38	Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). <i>Cancer Research</i> , 2020, 80, CT014-CT014.	0.4	45
39	Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 104-104.	0.8	4
40	Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. <i>Cancers</i> , 2019, 11, 817.	1.7	11
41	Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?. <i>Cancers</i> , 2019, 11, 834.	1.7	41
42	Defining a mutational signature for endometrial cancer screening and early detection. <i>Cancer Epidemiology</i> , 2019, 61, 129-132.	0.8	7
43	Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. <i>Annals of Oncology</i> , 2019, 30, 1370-1380.	0.6	171
44	New perspectives on screening and early detection of endometrial cancer. <i>International Journal of Cancer</i> , 2019, 145, 3194-3206.	2.3	58
45	PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 490-503.	0.8	255
46	Clinical predictors of survival in metastatic uveal melanoma. <i>Japanese Journal of Ophthalmology</i> , 2019, 63, 197-209.	0.9	31
47	Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 408-419.	5.1	276
48	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 1375-1383.	1.9	22
49	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. <i>Cancer Cell</i> , 2019, 36, 613-629.e7.	7.7	99
50	Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients. <i>Gynecologic Oncology</i> , 2019, 152, 270-277.	0.6	12
51	A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. <i>Human Gene Therapy</i> , 2019, 30, 352-364.	1.4	66
52	Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5027-5027.	0.8	7
53	Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5029-5029.	0.8	2
54	Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5086-TPS5086.	0.8	5

#	ARTICLE	IF	CITATIONS
55	KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology, 2019, 37, TPS9598-TPS9598.	0.8	5
56	Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 145-145.	0.8	43
57	Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 170-170.	0.8	3
58	Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.. Journal of Clinical Oncology, 2019, 37, 216-216.	0.8	8
59	Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.. Journal of Clinical Oncology, 2019, 37, 264-264.	0.8	4
60	Correlation between time to PSA progression (TTPP), radiographic progression-free survival (rPFS) and overall survival (OS) in first-line abiraterone/enzalutamide (Abi/Enza) and docetaxel (Doc) treated patients in a prospective cohort study.. Journal of Clinical Oncology, 2019, 37, 267-267.	0.8	2
61	A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.. Journal of Clinical Oncology, 2019, 37, TPS328-TPS328.	0.8	0
62	Abstract 727: Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies. Cancer Research, 2019, 79, 727-727.	0.4	3
63	A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Clinical Cancer Research, 2018, 24, 3717-3728.	3.2	267
64	Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent. Clinical Cancer Research, 2018, 24, 3755-3766.	3.2	17
65	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. Pathobiology, 2018, 85, 35-40.	1.9	26
66	SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clinical and Translational Oncology, 2018, 20, 57-68.	1.2	17
67	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). Journal of Clinical Oncology, 2018, 36, 1232-1239.	0.8	207
68	Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma. Cancer Research and Treatment, 2018, 50, 1130-1139.	1.3	18
69	Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. Cancer and Metastasis Reviews, 2018, 37, 335-345.	2.7	23
70	Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer. Oncotarget, 2018, 9, 15968-15983.	0.8	15
71	Outcomes of metastatic castration resistant prostate cancer (mCRPC) patients with DNA repair germline mutations (gDDR) following first taxane-based treatment.. Journal of Clinical Oncology, 2018, 36, 247-247.	0.8	0
72	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80

#	ARTICLE	IF	CITATIONS
73	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. <i>Clinical and Translational Oncology</i> , 2017, 19, 761-768.	1.2	12
74	AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1297-1310.	0.3	40
75	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 171-190.	2.0	22
76	Molecular approaches for classifying endometrial carcinoma. <i>Gynecologic Oncology</i> , 2017, 145, 200-207.	0.6	137
77	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-47.	0.8	577
78	TGF β 2 Controls Ovarian Cancer Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1658.	1.8	26
79	Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9533-9533.	0.8	13
80	Molecular and clinicopathological classification of high risk endometrial cancer (EC) treated with concurrent chemoradiation therapy (CCT).. <i>Journal of Clinical Oncology</i> , 2017, 35, e17110-e17110.	0.8	0
81	Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma. <i>Eye</i> , 2016, 30, 833-842.	1.1	21
82	Clinical outcomes in metastatic uveal melanoma treated with PD α 1 and PD α L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288
83	Immunotherapy in Endometrial Cancer: In the Nick of Time. <i>Clinical Cancer Research</i> , 2016, 22, 5623-5625.	3.2	28
84	Dynamic Change of Polarity in Primary Cultured Spheroids of Human Colorectal Adenocarcinoma and Its Role in Metastasis. <i>American Journal of Pathology</i> , 2016, 186, 899-911.	1.9	34
85	Uveal melanoma as a target for immune-therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 172-172.	0.7	63
86	Pembrolizumab expanded access program (EAP) in Spain: clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21029-e21029.	0.8	0
87	INTRAVITREAL DEXAMETHASONE IMPLANT FOR RADIATION MACULOPATHY SECONDARY TO PLAQUE BRACHYTHERAPY IN CHOROIDAL MELANOMA. <i>Retina</i> , 2015, 35, 1890-1897.	1.0	23
88	ME20-S as a Potential Biomarker for the Evaluation of Uveal Melanoma. , 2015, 56, 7007.		9
89	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1925-1934.	3.2	36
90	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. <i>International Journal of Cancer</i> , 2013, 133, 235-246.	2.3	16

#	ARTICLE	IF	CITATIONS
91	Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors. <i>BMC Cancer</i> , 2013, 13, 382.	1.1	21
92	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	13.9	2,412
93	Endoresection Versus Iodine-125 Plaque Brachytherapy for the Treatment of Choroidal Melanoma. <i>American Journal of Ophthalmology</i> , 2013, 156, 334-342.e1.	1.7	28
94	Prostatic sarcoma after conservative treatment with brachytherapy for low-risk prostate cancer. <i>Acta Oncol</i> , 2013, 52, 1215-1216.	0.8	8
95	Relative survival of patients with uveal melanoma managed in a single center. <i>Melanoma Research</i> , 2012, 22, 271-277.	0.6	20
96	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 341-352.	2.0	11
97	Epigenetic disruption of cadherin-11 in human cancer metastasis. <i>Journal of Pathology</i> , 2012, 228, 230-240.	2.1	60
98	Metastatic uveal melanoma. <i>Melanoma Research</i> , 2011, 21, 217-222.	0.6	46
99	Uveal Melanoma and BRCA1/BRCA2 Genes: A Relationship That Needs Further Investigation. <i>Journal of Clinical Oncology</i> , 2011, 29, e827-e829.	0.8	22
100	Serum and Tissue Profiling in Bladder Cancer Combining Protein and Tissue Arrays. <i>Journal of Proteome Research</i> , 2010, 9, 164-173.	1.8	30
101	Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 3384-3395.	3.2	57
102	Discovery of myopodin methylation in bladder cancer. <i>Journal of Pathology</i> , 2008, 216, 111-119.	2.1	27
103	Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5416-5421.	0.8	117